# Avelumab Program Rollover Study

> **NCT03815643** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 205 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03815643
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-22
- **Primary completion:** 2026-08-21
- **Final completion:** 2026-08-21
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03815643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03815643, "Avelumab Program Rollover Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03815643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*